---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-282705"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2023-11-24T23:59:59+00:00"
generated_at: "2026-06-07T21:54:13.020972+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Director Ole Isacson resigns from Cyclerion board; replacement to be named

## Summary
- Ole Isacson, M.D., Ph.D., resigned as director effective November 19, 2023.
- He served as Chair of Compensation Committee and member of Audit Committee.
- No disagreement with Cyclerion on operations, policies, or practices.
- Company expects to appoint a new outside director shortly.

## SEC filing metadata
- accession: 0001193125-23-282705
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2023-11-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000119312523282705/0001193125-23-282705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000119312523282705/d600226d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-282705
- JSON: https://secwatch.observer/filing/0001193125-23-282705.json
- Plain text: https://secwatch.observer/filing/0001193125-23-282705.txt

## Key facts
- Executive change
  Ole Isacson resigned as director at Cyclerion Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: On November 19, 2023, Ole Isacson, M.D., Ph.D., tendered his resignation as a director of Cyclerion Therapeutics, Inc. (the “Company”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000119312523282705/0001193125-23-282705-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.